Haematologica, Vol 92, Issue 11, e118-e119 doi:10.3324/haematol.11841
Copyright © 2007 by Ferrata Storti Foundation
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Helbig, G.
Right arrow Articles by Holowiecki, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Helbig, G.
Right arrow Articles by Holowiecki, J.

Online Only Articles

Interferon {alpha} induces a good molecular response in a patient with chronic eosinophilic leukemia (CEL) carrying the JAK2V617F point mutation

G. Helbig1,, B. Stella-Holowiecka1, M. Majewski2, M. Lewandowska2, J. Holowiecki1

1 Departament of Haematology and Bone Marrow Transplantation, Silesian Medical University, Katowice, Poland;
2 Institute of Hematology and Transfusion Medicine, Warsaw, Poland

Correspondence: Grzegorz Helbig, MD. Departament of Haematology and Bone Marrow Transplantation, Silesian Medical University, 40-027 Katowice, Dabrowski str. 25, Poland Tel: +48.322591236, Fax: +48.322554985. E-mail: ghelbig{at}o2.pl

The JAK2 V617F point mutation is very rare in hypereosinophilic syndome and/or chronic eosinophilic leukemia. Here we report on a patient with chronic eosinophilic leukemia and detectable JAK2 mutant clone, who achieved a good molecular response to interferon {alpha}-2a after 4 months of treatment. The molecular response correlated with only moderate haematological improvement

Key words: JAK2 V617F mutation, interferon {alpha}, hypereosinophilic syndrome, chronic eosinophilic leukemia, molecular response.